Denali Therapeutics financials
$20.81−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $330.5M | $108.5M | $48.7M | $335.7M | $26.7M | $129.2M | $0.00 |
| Gross profit | $0.00 | $0.00 | $330.5M | $108.5M | $48.7M | $335.7M | $26.7M | $129.2M | $0.00 |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating income | -$555.3M | -$501.9M | -$196.7M | -$340.7M | -$295.8M | $62.7M | -$213.2M | -$46.4M | -$90.1M |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M | -$290.6M | $71.1M | -$197.6M | -$36.2M | -$88.2M |
| Net margin | — | — | −43.9% | −300.6% | −597.2% | 21.2% | −740.7% | −28.1% | — |
| Diluted EPS | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.63 | $-2.07 | $-0.39 | $-5.89 |
| EBITDA | -$544.2M | -$494.1M | -$180.0M | -$332.0M | -$287.2M | $71.2M | -$205.2M | -$39.0M | -$87.1M |
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M | $416.2M | -$151.6M | $50.1M | -$76.6M |
| Free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M | -$219.9M | $413.1M | -$169.5M | $46.7M | -$79.5M |
| Diluted shares | 172.6M | 164.5M | 137.4M | 125.5M | 121.5M | 112.7M | 95.6M | 92.6M | 15.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $205.3M | $175.0M | $127.1M | $218.0M | $293.5M | $507.1M |
| Short-term investments | $662.6M | $657.4M | $907.4M | $1.12B | $571.9M | $962.6M |
| Total debt | $5.5M | $5.6M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B | $1.60B |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M | $453.7M |
| Shareholders' equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.3M | $1.15B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology